RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 17 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 17

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Tsinghua Changgung Hospital北京清华长庚医院BeijingHospital page
  2. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  3. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  4. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  5. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  6. Study siteFirst Hospital of Shanxi Medical University山西医科大学第一医院TaiyuanHospital page
  7. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  8. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  9. Study siteLanzhou University Second Hospital兰州大学第二医院LanzhouHospital page
  10. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  11. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  12. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  13. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  14. Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
  15. Study siteShanghai General Hospital上海市第一人民医院ShanghaiHospital page
  16. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
  17. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06989437, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy

    Inclusion criterion 4

  3. ECOG PS ≤1 with life expectancy of at least 4 months

    Inclusion criterion 5

  4. Renal disease requiring dialysis or eGFR <30 mL/min/1.73m2

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06989437, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key inclusion Criteria:

  • Signed Informed Consent Document
  • Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma
  • Cachexia defined by Fearon criteria of weight loss
  • Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy
  • ECOG PS ≤1 with life expectancy of at least 4 months

Key Exclusion Criteria:

  • Current active reversible causes of decreased food intake
  • Cachexia caused by other reasons
  • Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification
  • Left ventricular ejection fraction <50%
  • Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization
  • History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody
  • History of allergy or hypersensitivity to any of the chemotherapeutics or any of their excipients
  • Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma, symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases
  • Inadequate liver function
  • Renal disease requiring dialysis or eGFR <30 mL/min/1.73m2

Quoted from ClinicalTrials.gov, NCT06989437, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06989437, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06989437